These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6452200)

  • 21. Antitumor activity and toxicity of methyl 6-[3-(2-chloroethyl)- 3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside in experimental animals.
    Fujimoto S; Tashiro T; Ogawa M
    Gan; 1984 Oct; 75(10):937-46. PubMed ID: 6510639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship of structure to anticancer activity and toxicity of the nitrosoureas in animal systems.
    Johnston TP; Montgomery JA
    Cancer Treat Rep; 1986 Jan; 70(1):13-30. PubMed ID: 2935250
    [No Abstract]   [Full Text] [Related]  

  • 23. Phase I evaluation of chlorozotocin (NSC-178248): weekly schedule.
    Moriconi WJ; Taylor S; Slavik M; Belt RJ; Haas CD; Hoogstraten B
    Invest New Drugs; 1985; 3(1):57-62. PubMed ID: 3157661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of a new nitrosourea, CGP 6809, given every 2 weeks.
    Creaven PJ; Cowens JW; Huben R; Petrelli N; Karakousis C; Traynor D
    Cancer Chemother Pharmacol; 1989; 23(4):266-7. PubMed ID: 2924383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of cystemustine, a new cysteamine (2-chloroethyl) nitrosourea: an intrapatient escalation scheme.
    Mathé G; Misset JL; Triana BK; Godenèche D; Madelmont JC; Meyniel G
    Drugs Exp Clin Res; 1992; 18(4):155-8. PubMed ID: 1451646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of CCNU (NSC-79037) in the treatment of advanced gastrointestinal cancer.
    Klaassen DJ; Rapp E
    Cancer Chemother Rep; 1974; 58(5 Pt 1):667-9. PubMed ID: 4426046
    [No Abstract]   [Full Text] [Related]  

  • 27. Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma.
    Von Hoff DD; Amato DA; Kaufman JH; Falkson G; Cunningham TJ
    Am J Clin Oncol; 1984 Apr; 7(2):135-9. PubMed ID: 6230929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contributions of nitrosoureas to cancer treatment.
    Mitchell EP; Schein PS
    Cancer Treat Rep; 1986 Jan; 70(1):31-41. PubMed ID: 3002621
    [No Abstract]   [Full Text] [Related]  

  • 29. [Phase I study on oral administration of methyl-6-[[[(2-chloroethyl) nitrosoamino] carbonyl] amino]-6-deoxy-alpha-D-glucopyranoside (MCNU)].
    Kanamaru A; Nagai K; Fujita S; Masaoka T; Takubo T; Kitani T; Taniguchi N; Horiuchi A; Tsubaki K; Kawagoe H; Hirata M; Yonezawa T; Tsubakio T; Yasunaga K; Okamoto Y; Fujitake H; Ohkubo A
    Gan To Kagaku Ryoho; 1983 Aug; 10(8):1831-7. PubMed ID: 6882006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Phase II study of a new nitrosourea derivative, MCNU, in tablet form. Takai Blood Cancer Study Group].
    Kobayashi T; Tanaka I; Shirakawa S; Fujiwara Y; Hirota Y; Kobayashi M; Ohno R; Yamada H; Mitomo Y; Yamamoto M
    Gan To Kagaku Ryoho; 1987 Apr; 14(4):1079-85. PubMed ID: 3566304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new nitrosourea derivative TA-077, 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea. I. Comparative study on antitumor activity.
    Fujimoto S; Ogawa M
    Cancer Chemother Pharmacol; 1982; 9(3):134-9. PubMed ID: 6218931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I trial of chlorozotocin.
    Gralla RJ; Tan CT; Young CW
    Cancer Treat Rep; 1979 Jan; 63(1):17-20. PubMed ID: 154363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beneficial treatment with methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside in a patient with primary myelofibrosis.
    Asano Y; Shimokawa M; Okabe H; Sanefuji H; Kato K
    Acta Haematol; 1991; 85(2):103-4. PubMed ID: 2024552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PCNU Phase I study in the North California Oncology Group.
    Friedman MA
    Recent Results Cancer Res; 1981; 76():125-9. PubMed ID: 7232846
    [No Abstract]   [Full Text] [Related]  

  • 35. [Phase I study of 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea (TA-077). Phase I Study Group].
    Gan To Kagaku Ryoho; 1986 Jul; 13(7):2425-33. PubMed ID: 3729497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cure rates and tumor resistance in cured mice after nitrosourea treatment of EMT6 ascites tumors.
    Feola JM; Maruyama Y
    Oncology; 1986; 43(6):372-7. PubMed ID: 2949185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor activity of chlorozotocin (NSC-178748).
    Ungerleider RS
    Cancer Treat Rev; 1980 Dec; 7(4):191-5. PubMed ID: 6452199
    [No Abstract]   [Full Text] [Related]  

  • 38. [Preliminary results of phase I and II clinical trials of RFCNU, a new nitrosourea sugar derivative, in digestive tract tumours].
    Mathé G; Serrou B; Hayat M; De Vassal F; Misset JL; Schwarzenberg L; Machover D; Ribaud P; Belpomme D; Jasmin C; Musset M; Montero JL; Imbach JL
    Biomedicine; 1977 Nov; 27(8):294-7. PubMed ID: 339971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TCNU in advanced renal cancer. Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
    Van Oosterom AT; Droz JP; Fossa ST; Bono AV; Splinter TA; Verbaeys AJ; Keizer J; De Pauw M; Sylvester R
    Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1889-90. PubMed ID: 2632270
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase II trial of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea in small cell cancer of the lung.
    Chapman RA; Natale RB; Young CW; Wittes RE
    Am J Clin Oncol; 1984 Oct; 7(5):413-4. PubMed ID: 6095639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.